Drug intelligence / Profile preview

anti-BCMA CAR-T cells

Development stage: Phase 2
Lead developer: Shanghai HRAIN Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

Anti-BCMA CAR-T cells are a type of adoptive cell therapy where a patient's T cells are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the B-cell maturation antigen (BCMA) found on the surface of multiple myeloma cells. This therapy aims to redirect the patient's immune system to recognize and eliminate cancer cells. It has shown promising results in treating relapsed/refractory multiple myeloma (RRMM), extramedullary multiple myeloma (EMM), plasma cell leukemia (PCL), and has been explored for POEMS syndrome.

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on anti-BCMA CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-BCMA CAR-T cells.

Explore the full profile